Transgenic mouse strains offer the prospect of signi cant bene ts in the in vivo assessment of carcinogenic potential. The European Regulatory Authorities have been supportive of their inclusion as one of the second-test options in the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human use (ICH). However, there is a concern regarding premature systematic use of these models. At present, the information from the International Life Sciences Institute (ILSI) project suggests that the transgenic models under study are similarly sensitive to genotoxic pharmaceuticals . There are apparently some false negatives and false positives. For regulatory purposes, it is not yet possible to differentiate the models with respect to hazard identi cation and risk assessment . The evaluation of the models has reached an interesting but, at certain points, equivocal stage. Based on the weight of evidence gathered thus far, regulatory authorities cannot neglect the outcome of such studies but need to be cautious in their interpretation of data from such models, and the application in risk assessment procedures .
INTRODUCTION
Recently developed transgenic mouse strains seem to offer the prospect of signi cant bene ts (eg, reductions in time, cost and animal usage) in the in vivo assessment of carcinogenic potential. The European regulatory authorities have welcomed the advent of such models and have been supportive of their inclusion as one of the second-test options in the ICH Guidelines on carcinogenicity testing. However, there have been ongoing concerns regarding their premature systematic inclusion in regulatory test programs. Prior to the introduction of the ICH Guidelines, following a detailed evaluation of several substantive carcinogenicity databases, the CPMP concluded that one high quality carcinogenicity study accompanied by appropriate metabolic and toxicokinetic data, in the most appropriate species (normally the rat), would suf ce for regulatory purposes. Thus, in the mid-tolate 1990s, the reliability of the new models and their "added value" compared to a conventional rat bioassay and genetic toxicity program appeared uncertain. However, it was acknowledged that the transgenic (also "knockout") models had the potential to shed light on mechanistic aspects of cancer induction. 
DISCUSSION
During the Safety Working Party meeting in June 1998, these conclusions with respect to the new models were emphasized. The evaluation of the "phenolphthalein case" has raised many issues and the CPMP indicated that the p53 / mouse study performed could not be used at that time to provide information on the potency of a carcinogenic and/or genotoxic risk of phenolphthalein to humans (1) .
At this stage of model development, several questions may still be put forward, and the European Authorities prefer to raise questions rather than express strong positions:
What is the difference between the response in transgenic and wild-type mice, particularly with respect to doseresponse and organ-speci c tumour pro le? What is the appropriate application of these models in the context of human cancer risk assessment? What is the relation between the outcome of a study in the transgenic animals and genotoxicity data of the compound? Thus far, mainly genotoxic compounds are positive in these models. What is the value of genotoxic compounds as human pharmaceuticals? Will they only be used as cytostatics?
What are we looking for in the case of human pharmaceuticals? Do we need these models? * Genotoxic compounds will be detected using the genotoxicity battery.
-Request for a study with a predictable result is useless. -A negative result of a clearly positive genotoxic compound is hardly interpretable. (Is it a false negative?) * Less than 3% of human pharmaceuticals for chronic administration are really genotoxic (6), although a higher percentage induce questionable results in genotoxicity tests (3). VAN DER LAAN ET AL TOXICOLOGIC PATHOLOGY * Equivocal compounds in this respect might pro t from these models (although again we should know the risk for a false negative).
Pharmaceutical companies might be able to speed the clinical development of a pharmaceutical based on e-business. In such cases, life-span carcinogenicity studies are more and more the rate-limiting step at the end of the developmental process of a compound. Is it possible to reduce the duration of the life-span carcinogenicity studies? IARC carcinogens (most of them are genotoxic) were positive within 18 months (2) . The weight-of-evidence approach based on the complete package of pharmacology and toxicology and on rat carcinogenicity studies if necessary including mechanistic studies (4) might give suf cient data to explain preneoplastic lesions seen after 12 months. Rats are suf ciently sensitive (if metabolism of the compound is comparable with respect to humans) to detect carcinogenicity of nongenotoxic compounds after 24 months, maybe even after 18 or 12 months. Techniques should be developed to detect potentially uncontrolled proliferative effects earlier.
Short-or medium-term assays may be helpful to provide more mechanistic insight in the tumorigenic action if for example in such a model DNA-changes can be detected, differentiating between genotoxic and nongenotoxi c compounds. Short-term transgenic models might be useful if genotoxicity data are equivocal or if mechanistic data in rats are insufcient to explain the mechanism of carcinogenicity. Such a test is not a replacement of the genotoxicity battery but might be used to con rm the carcinogenic risk of the genotoxic event.
Models Should Detect Compounds Relevant to the Human
Situation: Genotoxic compounds are supposed to be carcinogenic (5) , so models should detect these. Many nongenotoxic rodent carcinogens (eg, peroxisome proliferators) are not expected to be carcinogenic in humans, so models detecting cancer with these types of compounds should be avoided, ideally (4) . Newborn mice will detect mutagenic compounds. However, the data are insuf cient to know whether all human carcinogens will be detected because weak genotoxic compounds have not been tested using the ILSI protocol. The question is whether there is an added value to the genotoxicity battery? Compounds identi ed in the newborn mouse assay as carcinogenic have been detected already in the genotoxicity battery as compounds at risk.
Do the Models Provide Additional Mechanistic Insight as
Promised?: The relationship between the hypothesis and the outcome of the studies with individual compounds, in a speci c model, is not yet elucidated.
What do we learn from the positive outcome with hormones, DES and estradiol, in certain models? What about the positive outcome of some of the studies with peroxisome proliferators and the negativity of p53 for the three peroxisome proliferators tested? Contrary to expectations for a genotoxic carcinogen, a low level of LOH (< 10%) was apparent in tumours caused by p-cresidine, whereas for other carcinogens a higher degree of LOH was found. DES has been indicated as a known human carcinogen based on its hormonal action. In the near future, the question should be answered whether the outcome in the p53 and in the XPA or the XPA/p53 studies is only related to the known hormonal mechanism, or if it indicates that there is an additional effect at the DNA-level that should be taken into consideration in the risk assessment. Also the positive outcome obtained in the Tg AC mouse by the dermal route need further clari cation.
The outcome of some studies with peroxisome proliferators leads to a deep discussion. The interpretation of these studies is not always easy, as expected, since no parallel data on the effects in wild-type animals are present. It might be that with very aggressive nongenotoxic rodent carcinogens at high doses, and under suf ciently long lasting exposure, even this type of transgenic animals will react as if the compounds are directly damaging DNA. It is important to discuss this issue further. Apparently, the outcome of the studies with transgenic animals is negative in many cases in which the long-term study would be positive, like some rodent carcinogens/putative human noncarcinogens as haloperidol and sulfamethoxazole. The relevance of a positive outcome therefore is increased, and stresses the need to be assured that a positive result, with a peroxisome proliferator for example, should be interpreted as really troublesome, or if not, why.
Are the Transgenic Animals to be Used as Stand Alone or in Combination with Wild-Type Animals?
: Should a difference (qualitative, quantitative, or both) from the wild-type be an additional criterion? For example, administration of cyclosporin A in XPA mice induces lymphomas in males as well as in females. However, the wild-type females showed tumours too, and further research is necessary to see whether the deletion of the XPA changes the sensitivity of the animals for cyclosporin A. This is also true for the hormones DES and 17b -estradiol.
Is One Model More Appropriate Than Another?: For industry as well as for regulators it is important to make a choice in practical cases. SHE cell assay: This assay only con rms the outcome of carcinogenicity data of conventional long-term rodent studies, without adding further knowledge. For nal risk assessment this assay is not useful, therefore. Theoretically, it might be used as a rapid screening to select uncomplicated compounds. It has from that point of view no regulatory weight of evidence. Neonatal mice for genotoxic compounds: As pointed out above, what is the added value in relation to the genotoxicity battery? If only strong mutagenic compounds are positive in this assay, then the Ames test is suf cient for hazard identi cation. But what about weak genotoxic compounds? Tg AC for compounds to be applied dermally? Differentiation between nongenotoxic and genotoxic compounds is still not clear, and the differences between the oral and dermal route raise additional dif culties. The outcome of a study does not answer the question whether a mechanism is involved that might be relevant to the human situation. If further data are present with respect to clo brate Vol. 30, No. 1, 2002 ALTERNATIVES MODELS IN CARCINOGENICITY TESTING 159 or WY-14643 this should be evaluated. The positivity of cyclosporin, DES, and estradiol by the dermal route in this model is also dif cult to explain. Differences in outcome between the other transgenic models rasH2, p53, XPA, and XPA/p53 are minor although the experience with the different models is not of the same extent. Some puzzling questions still remain: * Why is melphalan equivocal rather than positive in rasH2? Melphalan is known to be a human carcinogen, although used as an anticancer agent, too. * Why is glycidol negative in p53? Although glycidol is not an ILSI-list compound, the evidence that it is a genotoxic carcinogen is strong. Why is this a false negative? * Why is clo brate positive in rasH2 and why is WY-14643 positive in XPA? Is this a model-related or a productrelated issue? This problem is similar to that seen in Tg AC mice, mentioned before. Clo brate might be a very strong promotor. Maybe the reason is that with high concentrations, and long exposure, the physiologica l system of the animal is overloaded.
The difference in mechanistic hypothesis between rasH2 (introduction of oncogene) and p53 (deletion of suppressor gene) versus XPA (deletion of part of the DNA-repair system) for explaining the higher sensitivity to carcinogens is fundamental. Should this have consequences? Should both deletions of p53 and XPA-related repair system increase the sensitivity? In fact, this point has received hardly any attention thus far. Explanations for differences in response with different strains of p53 mice (positive and negative responses obtained for phenolphthalei n) remain elusive.
Taking all these considerations into account, a choice should be made. This is not an easy task. In many cases, the choice is based on pragmatic arguments, such as the experience of the study scientist and his/her network, and/or the availability of animals. Company representatives should be stimulated to be more explicit in their arguments to support their choice of model. CONCLUSIONS Nongenotoxic mechanisms are most important in assessing carcinogenic potential of pharmaceuticals. These mechanisms can be detected suf ciently in rats, if adequate protocols are used. Studies providing supportive evidence in mechanistic studies are more important than performing another long-term study. At present, the information available from the ILSI project suggests that the transgenic models (p53, XPA [or XPA/p53], and rasH2) are similarly sensitive to genotoxic pharmaceuticals. There are some false negatives (glycidol?) and false positives (peroxisome proliferators?). For regulatory purposes, it is not yet possible to differentiate the models with respect to hazard identi cation and risk assessment. The evaluation of the models has reached an interesting, but at certain points equivocal, stage. Based on the weight of evidence gathered thus far, regulatory authorities cannot neglect the outcome of studies utilizing alternative models. However, they need to be cautious in their interpretation of the data and in the application of data for human risk assessment.
